March 9, 2023 02:06 PM ESTUpdated 02:27 PM
Pharma
FDA+

FDA makes rare 'mis­in­for­ma­tion' com­ment on Lu­ci­ra's EUA for its at-home Covid-19 and flu test

Katherine Lewin

News Reporter

The FDA has re­leased a rare com­ment on what hap­pened dur­ing Lu­ci­ra Health’s EUA fil­ing for the first at-home Covid-19 and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times